Final published version
Licence: CC BY: Creative Commons Attribution 4.0 International License
Research output: Contribution to Journal/Magazine › Journal article › peer-review
Research output: Contribution to Journal/Magazine › Journal article › peer-review
}
TY - JOUR
T1 - Exponential growth, high prevalence of SARS-CoV-2, and vaccine effectiveness associated with the Delta variant
AU - COVID-19 Genomics UK (COG-UK) Consortium
AU - Elliott, Paul
AU - Haw, David
AU - Wang, Haowei
AU - Eales, Oliver
AU - Walters, Caroline E
AU - Ainslie, Kylie E C
AU - Atchison, Christina
AU - Fronterre, Claudio
AU - Diggle, Peter J
AU - Page, Andrew J
AU - Trotter, Alexander J
AU - Prosolek, Sophie J
AU - Ashby, Deborah
AU - Donnelly, Christl A
AU - Barclay, Wendy
AU - Taylor, Graham
AU - Cooke, Graham
AU - Ward, Helen
AU - Darzi, Ara
AU - Riley, Steven
AU - Robson, Samuel C
AU - Loman, Nicholas J
AU - Connor, Thomas R
AU - Golubchik, Tanya
AU - Martinez Nunez, Rocio T
AU - Ludden, Catherine
AU - Corden, Sally
AU - Johnston, Ian
AU - Bonsall, David
AU - Smith, Colin P
AU - Awan, Ali R
AU - Robertson, David L
AU - Todd, John A
AU - Jones, Christopher R
AU - Hutchings, Stephanie
AU - Williams, Thomas
AU - Moore, Christopher
AU - Davies, Robert
AU - Jones, Hannah
AU - Taylor, Sarah
AU - Taylor, Ben Ew
AU - Jones, Rachel
AU - Lowe, Helen L
AU - Baker, Paul
AU - Smith, Louise
AU - Lee, David
AU - Williams, David
AU - Brown, Paul E
AU - Baker, David J
AU - Brown, Rebecca
PY - 2021/12/17
Y1 - 2021/12/17
N2 - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections were rising during early summer 2021 in many countries as a result of the Delta variant. We assessed reverse transcription polymerase chain reaction swab positivity in the Real-time Assessment of Community Transmission–1 (REACT-1) study in England. During June and July 2021, we observed sustained exponential growth with an average doubling time of 25 days, driven by complete replacement of the Alpha variant by Delta and by high prevalence at younger, less-vaccinated ages. Prevalence among unvaccinated people [1.21% (95% credible interval 1.03%, 1.41%)] was three times that among double-vaccinated people [0.40% (95% credible interval 0.34%, 0.48%)]. However, after adjusting for age and other variables, vaccine effectiveness for double-vaccinated people was estimated at between ~50% and ~60% during this period in England. Increased social mixing in the presence of Delta had the potential to generate sustained growth in infections, even at high levels of vaccination.
AB - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections were rising during early summer 2021 in many countries as a result of the Delta variant. We assessed reverse transcription polymerase chain reaction swab positivity in the Real-time Assessment of Community Transmission–1 (REACT-1) study in England. During June and July 2021, we observed sustained exponential growth with an average doubling time of 25 days, driven by complete replacement of the Alpha variant by Delta and by high prevalence at younger, less-vaccinated ages. Prevalence among unvaccinated people [1.21% (95% credible interval 1.03%, 1.41%)] was three times that among double-vaccinated people [0.40% (95% credible interval 0.34%, 0.48%)]. However, after adjusting for age and other variables, vaccine effectiveness for double-vaccinated people was estimated at between ~50% and ~60% during this period in England. Increased social mixing in the presence of Delta had the potential to generate sustained growth in infections, even at high levels of vaccination.
U2 - 10.1126/science.abl9551
DO - 10.1126/science.abl9551
M3 - Journal article
C2 - 34726481
VL - 374
JO - Science
JF - Science
SN - 1095-9203
IS - 6574
M1 - eabl9551
ER -